Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 30, 2007 Brian Lawler	Bristol-Myers Isn't Standing in Place Brighter days seem ahead for Bristol-Myers Squibb, now that recent litigation has taken a major turn for the better.
The Motley Fool April 28, 2011 Brian Orelli	1 Year to P-Day, Bristol-Myers Squibb Looks Just Fine New drugs should help cushion the fall from the loss of Plavix.
BusinessWeek January 29, 2007 Arlene Weintraub	More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool April 29, 2004 Bill Mann	Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses.
BusinessWeek October 17, 2005 Amy Barrett	Prescription For Upheaval How the Medicare drug program is tightening the screws on Big Pharma.
The Motley Fool June 3, 2011 Brian Orelli	Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up.
The Motley Fool March 5, 2010 Brian Orelli	How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool September 13, 2006 Brian Lawler	What to Make of Bristol-Myers Take a good look at the industry to try to sort out the meaning of all the news and the rumors. Investing in a company based on a possible buyout is never a good idea when the possibility is based solely on rumors and analyst speculation.
The Motley Fool June 21, 2007 Billy Fisher	A Bull-Run at Bristol The strength of its oncology pipeline sets Bristol-Myers apart from its peers. Regardless of whether the company is ultimately taken over, shareholders are definitely in a better position than they have been in recent years.
The Motley Fool October 26, 2007 Billy Fisher	A Quarter to Boast About at Bristol Bristol-Myers announces a 22% rise in third-quarter revenue as Plavix sales continue to rise. Investors, take note.
The Motley Fool July 27, 2010 Brian Orelli	Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant.
The Motley Fool November 1, 2004 Brian Gorman	Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes.
The Motley Fool May 28, 2008 Brian Lawler	A Little-Noticed Drug Rejection The EU temporarily blocks Sanofi and Bristol-Myers' shot at extending a drug's lifespan.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
Pharmaceutical Executive August 1, 2005 Joanna Breitstein	Weathering the Storm Out from financial scandal, CEO Peter Dolan is steering Bristol-Myers Squibb's most productive pipeline yet.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
The Motley Fool September 8, 2011 Arlene Weintraub	Bristol-Pfizer Team on Alert as FDA Reviews Stroke-Prevention Drug From Rivals J&J and Bayer Who will come out ahead?
The Motley Fool June 30, 2010 Brian Orelli	When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions.
The Motley Fool September 7, 2010 Luke Timmerman	ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C.
The Motley Fool December 31, 2007 Brian Lawler	Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool March 15, 2010 Brian Orelli	Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison.
The Motley Fool June 7, 2010 Brian Orelli	Bristol Investors Go Crazy Wild. Are They Justified? Bristol-Myers Squibb is up a lot on an upgrade and some positive data coming out of the American Society of Clinical Oncology meeting, but investors need to be careful.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool January 25, 2006 Stephen D. Simpson	Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
The Motley Fool January 29, 2007 Brian Lawler	Bristol-Myers Blames the Generic Again The fourth quarter's financial results are dominated by generic competition.
The Motley Fool May 5, 2006 Stephen D. Simpson	Sanofi-Aventis Waits It Out This is the hurry up-and-wait part of the French pharma's story, with product approvals on the way soon, investors hope.
The Motley Fool May 1, 2007 Brian Lawler	Bristol-Myers Stops Spinning in Place Bristol-Myers releases first-quarter financial results. Investors, take note.
The Motley Fool November 1, 2006 Brian Lawler	Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note.
The Motley Fool January 13, 2012 Sean Williams	CEO Gaffe of the Week: Bristol-Myers Squibb Some days, CEOs would be better off staying in bed.
The Motley Fool October 8, 2010 Luke Timmerman	Bristol-Myers Almost Ready to Seal the Deal With ZymoGenetics ZymoGenetics, one of the driving forces of Seattle biotech the past 30 years, is about to become a thing of the past.
The Motley Fool January 5, 2010 Brian Orelli	Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool February 25, 2004 Brian Gorman	Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry.
The Motley Fool August 31, 2009 Brian Orelli	Thinning Out Plavix's Monopoly Until now sanofi-aventis' and Bristol-Myers Squibb's Plavix didn't have a monopoly on the blood-thinning market, but it was pretty darn close. But now, another competitor's on the way.
The Motley Fool September 1, 2006 Brian Lawler	Bristol-Myers and Sanofi Get Apotex to Stop A temporary injunction against generic drug manufacturer Apotex over patents involving Plavix means big news for all the companies involved.
The Motley Fool July 31, 2006 Stephen D. Simpson	More Plavix Headaches for Bristol-Myers Problems with a Plavix settlement put a large chunk of earnings at risk. Investors, take note.
The Motley Fool May 13, 2008 Brian Lawler	Sanofi Can't Shake the Generics A new threat to the pharmaceutical's top drug may have arrived.
The Motley Fool June 21, 2010 Luke Timmerman	Bristol-Myers Dumps Exelixis Drug There is an exit payment for Exelixis.
The Motley Fool December 18, 2007 Brian Orelli	Bristol-Myers' Sleeker Image Just 12 days after announcing its restructuring plan, Bristol-Myers Squibb has found a buyer for its medical-imaging division and plans to close the deal by the end of next month.
The Motley Fool October 30, 2009 Brian Orelli	Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future.
The Motley Fool June 19, 2007 Brian Lawler	Victory for Sanofi and Bristol-Myers The pharmaceutical gains a crucial legal victory for its top compound. Investors, take note.
The Motley Fool May 11, 2009 Brian Orelli	Brilliant, Now Let's See the Data AstraZeneca's investors today should be cautiously optimistic about Brilinta. It could be a blockbuster for the company, but it may need some brilliant marketing to compete.
The Motley Fool September 30, 2011 David Williamson	This Week in Health Care Pharma news about Pfizer, AstraZeneca, and the multibillion-dollar battle to replace the maligned blood-thinner warfarin.
The Motley Fool January 9, 2012 Brian Orelli	3 Reasons Hep C Premiums Might Not Last Careful what you wish for.
The Motley Fool October 23, 2009 Brian Orelli	I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
The Motley Fool August 12, 2011 David Williamson	What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter?